Dream Games
Private Equity Round in 2025
Founded in 2019, Dream Games is a Turkish company based in Istanbul that specializes in developing high-quality mobile games. Combining technology and creativity, the company aims to create casual games that provide engaging experiences for players.
Skroutz.gr
Private Equity Round in 2020
Skroutz A.E., founded in 2005 and based in Acharnes, Greece, operates a leading product and price comparison portal, www.skroutz.gr. The platform connects consumers with over 3,500 online merchants, allowing more than 8 million unique visitors each month to compare prices on a wide range of products, including electronics, home furnishings, cosmetics, and clothing. Through its user-focused services, Skroutz has established itself as a prominent brand in the e-commerce sector, providing innovative solutions for both shoppers and merchants. The company not only serves the Greek market but has also expanded its operations internationally with projects in Turkey and the UK. With a workforce of over 240 employees, Skroutz generates annual revenues of approximately €10.5 million, showcasing its significant impact on the digital commerce landscape.
D-Marin
Acquisition in 2020
D-Marin is a company established to set high operational standards in marina management. Based in Athens, Greece, it specializes in providing comprehensive marina services, promoting recreational waterfront infrastructure, and creating value for its partners.
Recordati
Acquisition in 2018
Recordati, established in 1926 and headquartered in Milan, Italy, is an international pharmaceutical group dedicated to the research, development, manufacturing, and marketing of specialty pharmaceuticals. With over 3,300 employees, the company operates in various regions, including major European countries, Russia, Turkey, and the United States. Recordati's field force of more than 1,700 medical representatives promotes a diverse portfolio of innovative medications, focusing on both proprietary products and licensed therapies in areas such as cardiovascular health, urogenital disorders, and rare diseases. The company’s revenue is primarily generated from its operations in Italy, followed by the United States, France, and Germany. Recordati is known for its strategic partnerships in acquiring new product licenses and is committed to developing treatments for rare diseases alongside primary care therapies.